Tyroserleutide

酪丝亮肽

Report date: 2023/05/31 20:00:53
NME

Base Information

Drug NameTyroserleutide
Drug Alias NameYSLCMS-024alpha-BCP[7-9]
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCalmodulin antagonistsIntercellular adhesion molecule-1 inhibitors
TargetsIntercellular adhesion molecule-1Calmodulin
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaDiscontinued
Originator CompaniesChina Medical System Holdings Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesKangzhe (Hunan) Pharmaceutical Co LtdShenzhen Kangzhe Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A